logo
  

Myriad Genetics Inc. (MYGN) Broke Out To A New High After Q1 Profit Beat

Myriad Genetics Inc. (MYGN) reported first quarter EPS of $0.41 after the close Tuesday, up from $0.25 in the previous year. Analysts expected EPS of $0.35. The company expects to report second quarter EPS of $0.40 to $0.42 and between $1.60 and $1.65. The consensus estimates are for EPS of $0.42 and $1.64.

Myriad Genetics gapped up at the open Tuesday and climbed for the bulk of the afternoon. Shares finished up by 3.84 at $46.16 on above average volume. The stock broke out of a 2-week trading range and set a new high for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT